Adverum Biotechnologies, Inc.
ADVMNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for ADVM. That does not mean none is planned.
Get an email about ADVM's next catalysts
Track Adverum Biotechnologies (ADVM) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
Adverum Biotechnologies, Inc. (formerly known as Avalanche Biotechnologies) is a publicly traded clinical stage gene therapy company located in Redwood City, California. It is targeting unmet medical needs for serious ocular and rare diseases, including wet age-related macular degeneration (wet AMD).
Website| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
6E11 vg/eye of ADVM-022 | Phase 2 | Diabetic Macular Edema | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Adverum Biotechnologies, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Adverum Biotechnologies, Inc.'s (ADVM) pipeline across Phase 2. Its lead program is 6E11 vg/eye of ADVM-022 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Adverum Biotechnologies, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Adverum Biotechnologies, Inc. (ADVM) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ADVM biotech catalysts?→
Add ADVM to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Adverum Biotechnologies, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.